Alexandra S. Helbo

Dual inhibition of DNMTs and EZH2 can overcome both intrinsic and acquired resistance of myeloma cells to IMiDs in a cereblon‐independent manner

Konstantinos Dimopoulos, Alexandra S. Helbo, Helga Fibiger Munch‐Petersen et al. · Molecular Oncology · 2017 · 83 citations · Full text

Hematological Malignancy, Tumor Biology, Dual Inhibition +14

Activation of a Subset of Evolutionarily Young Transposable Elements and Innate Immunity Are Linked to Clinical Responses to 5-Azacytidine

Hitoshi Ohtani, Andreas Due Ørskov, Alexandra S. Helbo et al. · Cancer Research · 2020 · 63 citations · Full text

Nucleosome Positioning and NDR Structure at RNA Polymerase III Promoters

Alexandra S. Helbo, Fides D. Lay, Peter A. Jones et al. · Scientific Reports · 2017 · 39 citations · Full text

Histone Modifications, Epigenetic Change, Genetics +20

Tumor suppressor microRNAs are downregulated in myelodysplastic syndrome with spliceosome mutations

Derya Aslan, Christian Garde, Mette Katrine Nygaard et al. · Oncotarget · 2016 · 31 citations · Full text

Engineering, Pathology, Tumor Suppressor Micrornas +20

Hypermethylation of the VTRNA1-3 Promoter is Associated with Poor Outcome in Lower Risk Myelodysplastic Syndrome Patients

Alexandra S. Helbo, Marianne Bach Treppendahl, Derya Aslan et al. · Genes · 2015 · 29 citations · Full text

Histone Modifications, Poor Outcome, Epigenetic Change +17